JP2024500335A5 - - Google Patents

Info

Publication number
JP2024500335A5
JP2024500335A5 JP2023534635A JP2023534635A JP2024500335A5 JP 2024500335 A5 JP2024500335 A5 JP 2024500335A5 JP 2023534635 A JP2023534635 A JP 2023534635A JP 2023534635 A JP2023534635 A JP 2023534635A JP 2024500335 A5 JP2024500335 A5 JP 2024500335A5
Authority
JP
Japan
Prior art keywords
polypeptide
complex according
seq
isolated polypeptide
polypeptide complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062233 external-priority patent/WO2022125562A1/en
Publication of JP2024500335A publication Critical patent/JP2024500335A/ja
Publication of JP2024500335A5 publication Critical patent/JP2024500335A5/ja
Pending legal-status Critical Current

Links

JP2023534635A 2020-12-08 2021-12-07 抗cd3結合ドメインのためのペプチド組成物および方法 Pending JP2024500335A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122820P 2020-12-08 2020-12-08
US63/122,820 2020-12-08
PCT/US2021/062233 WO2022125562A1 (en) 2020-12-08 2021-12-07 Peptide compositions and methods for anti-cd3 binding domains

Publications (2)

Publication Number Publication Date
JP2024500335A JP2024500335A (ja) 2024-01-09
JP2024500335A5 true JP2024500335A5 (cg-RX-API-DMAC7.html) 2024-12-12

Family

ID=81973732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534635A Pending JP2024500335A (ja) 2020-12-08 2021-12-07 抗cd3結合ドメインのためのペプチド組成物および方法

Country Status (9)

Country Link
US (1) US20240043536A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259177A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024500335A (cg-RX-API-DMAC7.html)
KR (1) KR20230137301A (cg-RX-API-DMAC7.html)
CN (1) CN116981682A (cg-RX-API-DMAC7.html)
AU (1) AU2021396507A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201401A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006733A (cg-RX-API-DMAC7.html)
WO (1) WO2022125562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
EP4615514A2 (en) * 2022-11-10 2025-09-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2017008844A1 (en) * 2015-07-14 2017-01-19 Biontech Ag Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
US20240034806A1 (en) * 2020-12-09 2024-02-01 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
EP4259193A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
AR125758A1 (es) * 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras

Similar Documents

Publication Publication Date Title
US11879005B2 (en) Hetero-dimeric multi-specific antibody format
US10913796B2 (en) Antibodies targeting Fc receptor-like 5 and methods of use
JP2025111463A5 (cg-RX-API-DMAC7.html)
JP2020114210A5 (cg-RX-API-DMAC7.html)
JP2021106617A5 (cg-RX-API-DMAC7.html)
RU2317999C2 (ru) SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2021136483A1 (en) Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
JP2021522162A5 (cg-RX-API-DMAC7.html)
JP2021159081A5 (cg-RX-API-DMAC7.html)
JP2021530251A5 (cg-RX-API-DMAC7.html)
JP2005507635A5 (cg-RX-API-DMAC7.html)
JP2023527609A5 (cg-RX-API-DMAC7.html)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2023548443A5 (cg-RX-API-DMAC7.html)
JP2024527288A5 (cg-RX-API-DMAC7.html)
HRP20161216T1 (hr) Farmaceutski pripravci s otpornošću na topljivi cea
JP2022527151A5 (cg-RX-API-DMAC7.html)
JP2020505919A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2011526249A5 (cg-RX-API-DMAC7.html)
JP2022543669A5 (cg-RX-API-DMAC7.html)
JP2024119984A5 (cg-RX-API-DMAC7.html)
JP2023506834A5 (cg-RX-API-DMAC7.html)
JP2021529524A5 (cg-RX-API-DMAC7.html)
CN1381461A (zh) 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用